Literature DB >> 9717878

No association between calcium channel blocker use and confirmed bleeding peptic ulcer disease.

W E Smalley1, W A Ray, J R Daugherty, M R Griffin.   

Abstract

Calcium channel antagonists are commonly used drugs that have recently been reported to be associated with an increased incidence of gastrointestinal hemorrhage. We performed a retrospective cohort study among 105,824 enrollees of the Tennessee Medicaid program 65 years of age or older between 1984 and 1986. Exposure to calcium channel blockers and other medications was determined from pharmacy files. Hospitalization for bleeding peptic ulcers was identified by hospital claims and verified by a review of the medical record. Univariate estimates of relative risk for current users of calcium channel blockers and beta-blocker users were 1.8 (95% confidence interval (CI) 1.2-2.7) and 1.1 (95% CI 0.7-1.6) (reference group was nonuse of either). After adjustment for potential confounders, the relative risks for bleeding peptic ulcer among current users of calcium channel blockers and beta blockers were 1.1 (95% CI 0.7-1.7) and 1.0 (95% CI 0.7-1.6), respectively, when compared with those who used neither drug. In this population, after controlling for important confounders, there was no increased risk for hospitalization with bleeding peptic ulcer among users of calcium channel blockers.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9717878     DOI: 10.1093/oxfordjournals.aje.a009652

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  4 in total

1.  Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs.

Authors:  J Weil; M J Langman; P Wainwright; D H Lawson; M Rawlins; R F Logan; T P Brown; M P Vessey; M Murphy; D G Colin-Jones
Journal:  Gut       Date:  2000-01       Impact factor: 23.059

2.  Characteristics and outcomes of acute upper gastrointestinal bleeding after therapeutic endoscopy in the elderly.

Authors:  Phunchai Charatcharoenwitthaya; Nonthalee Pausawasdi; Nuttiya Laosanguaneak; Jakkrapan Bubthamala; Tawesak Tanwandee; Somchai Leelakusolvong
Journal:  World J Gastroenterol       Date:  2011-08-28       Impact factor: 5.742

3.  Risk of hospitalized and non-hospitalized gastrointestinal bleeding in ALLHAT trial participants receiving diuretic, ACE-inhibitor, or calcium-channel blocker.

Authors:  Xianglin L Du; Lara M Simpson; Brian C Tandy; Judith L Bettencourt; Barry R Davis
Journal:  PLoS One       Date:  2021-11-18       Impact factor: 3.240

4.  Risk of hospitalized gastrointestinal bleeding in persons randomized to diuretic, ACE-inhibitor, or calcium-channel blocker in ALLHAT.

Authors:  William Phillips; Linda B Piller; Jeff D Williamson; Jeffrey Whittle; Syed Z A Jafri; Charles E Ford; Paula T Einhorn; Suzanne Oparil; Curt D Furberg; Richard H Grimm; Michael H Alderman; Barry R Davis; Jeffrey L Probstfield
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-08-07       Impact factor: 3.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.